- Explore principles of treatment sequencing in different case scenarios while utilizing novel antibody drug conjugates in the context of rapidly evolving approved therapies.
- Consider multidisciplinary considerations of managing potential toxicities of therapies and adaptation to women's normal physiologies and endocrinological needs.
- Apply new concepts of HER2 low disease in the clinical setting.
08/30/2022 - 7:00am to 8:00am CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Nan Chen, MD, Sarah Shubeck, MD, Adam DuVall, MD, MPH